Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5825776 | Clinical Therapeutics | 2012 | 15 Pages |
Abstract
Results of this investigator-masked study with Chinese patients suggest LE suspension 0.2% was noninferior to olopatadine solution 0.1% for the treatment of SAC. Both LE suspension 0.2% and olopatadine solution 0.1% were well tolerated. ClinicalTrials.gov identifier: NCT01435460.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Lan PhD, Xinghuai PhD, Jia PhD, Lili PhD, Mingzhi PhD, Hong PhD, Linnong PhD, Yangshun PhD, Albert MS, Lipika MD, Byron MD,